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Abstract
Background: Comorbid psychiatric illness can undermine outcomes among homeless persons
undergoing addiction treatment, and psychiatric specialty care is not always readily available. The
prognosis for nonsubstance abuse psychiatric diagnoses among homeless persons receiving
behaviorally-based addiction treatment, however, is little studied.
Results: Data from an addiction treatment trial for 95 cocaine-dependent homeless persons
(1996–1998) were used to profile psychiatric diagnoses at baseline and 6 months, including mood-
related disorders (e.g. depression) and anxiety-related disorders (e.g. post-traumatic stress
disorder). Treatment interventions, including systematic reinforcement for goal attainment, were
behavioral in orientation. There was a 32% reduction in the prevalence of comorbid non-addiction
psychiatric disorder from baseline to 6 months, with similar reductions in the prevalence of mood
(-32%) and anxiety-related disorders (-20%) (p = 0.12).
Conclusion:  Among cocaine-dependent homeless persons with psychiatric comorbidity
undergoing behavioral addiction treatment, a reduction in comorbid psychiatric disorder
prevalence was observed over 6 months. Not all participants improved, suggesting that even
evidence-based addiction treatment will prove insufficient for a meaningful proportion of the dually
diagnosed homeless population.
Background
In 2004, homeless persons in the United States accounted
for 175,300 admissions to substance abuse treatment
facilities receiving public funding [1], with recent cocaine
use reported in 46% of those admissions [2]. Comorbid
psychiatric disorders are an important complicating factor
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in the treatment of homeless drug users. In a national sur-
vey, 3/4 of homeless persons with a past-year drug prob-
lem also had a current nonsubstance-related mental
health problem [3]. These figures are comparable to the
general population of persons seeking treatment for drug
use disorders. In the National Epidemiologic Survey on
Alcohol and Related Conditions (2001–02), among per-
sons who sought treatment for a current (past-year) drug
use disorder, 60% had an independent mood-related dis-
order (MRD) and 43% had an independent anxiety-
related disorder (ARD) during the same period [4].
Recent initiatives on homelessness make it important to
understand what psychiatric outcomes can be obtained
from behavioral addiction treatment programs serving
dually diagnosed homeless persons. Initiatives of the
United States federal government include a policy focus
on ending chronic homelessness [5-9], and the instigation
of 10-year homeless planning processes among 222 com-
munities across the United States (Personal Communica-
tion, Mary Ellen Hombs, United States Interagency
Council on Homelessness, August 3, 2006). Outcomes for
homeless persons are also of interest because 80% of
homeless single adults with nonaddiction mental health
problems do not receive services for those problems [10].
Further, only 35% of substance abuse treatment facilities
provide formal treatment for persons with comorbid
mental health disorders [11], meaning that formally inte-
grated dual diagnosis treatment programs, while poten-
tially ideal [12], are likely to remain inaccessible for many
dually diagnosed homeless persons.
Whether behavioral treatments for substance abuse in the
homeless [13,14] confer benefit for comorbid mental ill-
ness remains unclear. Some reports describe reductions in
psychiatric symptoms among persons undergoing addic-
tion treatment, potentially due to resolution of post-drug
dysphoric symptoms (including the post-cocaine
"crash"[15]), or remission of substance-induced mental
disorders [16]. Such data are not entirely informative for
homeless policy, however, due to: (a) with excep-
tions[12], insufficient representation of homeless persons
in reported samples; (b) a lack of formal diagnostic assess-
ment at the treatment follow-up; and (c) a paucity of stud-
ies regarding formal behavioral addiction treatment
approaches. Behavioral addiction treatments, defined as
manualized nonpharmacologic interventions for sub-
stance abuse [17], include modalities such as community
reinforcement, rewards for abstinence or other goal attain-
ment, and cognitive behavioral therapy. Such approaches
can be deployed in publicly funded addiction treatment
programs that receive homeless persons. However, a
review of the efficacy of behavioral therapies among
dually diagnosed cocaine dependent persons noted that
empiric data are notable mainly for their absence [18].
In response to a paucity of empirically validated treatment
options for dually diagnosed (non-psychotic) homeless
persons, we performed a secondary analysis of data from
a randomized behavioral addiction treatment trial for
homeless, non-psychotic, cocaine-abusing individuals,
focusing on non-substance abuse psychiatric outcomes.
The original trial intervention randomly assigned a behav-
ioral contingency management approach (including
abstinence contingent housing and paid vocational reha-
bilitation) to half of the participants while offering inten-
sive behavioral day treatment (including psychosocial,
cognitive behavioral, and rewards for nonsubstance-
related goal attainment) to all participants. Substance use
improved in both trial arms, but improved more in the
contingency management group, as has been reported
[19,20].
There was plausible basis to anticipate improvement in
non-substance abuse psychiatric diagnoses. Vocational
rehabilitation activities included social reinforcement,
including vouchers for purchase of goods in response to
goal accomplishment (for both trial arms). Individuals
within the contingency-managed housing trial arm addi-
tionally had access to program-provided housing and
work therapy dependent on the results of negative urine
toxicology screens. The treatment program activities there-
fore had elements of behavioral activation, access to rein-
forcers, and distraction from negative maladaptive
cognitions, features typical of cognitive-behavioral thera-
pies [21,22]. Further, it bore resemblance to milieu ther-
apy, which has a record of efficacy in depression [23].
The present examination sought to describe what
improvement, if any, transpired for non-addiction psychi-
atric disorders after treatment was offered for 6 months.
While this analysis takes account of trial arm, intensive
day treatment was offered to all participants in this study,
and this analysis assessed improvements in psychiatric
status for persons with mood-related disorders and anxi-
ety-related disorders for participants in both trial arms.
Methods
The original treatment trial was conducted between April
1995 and August 1996 [19].
Participants
Participants in the clinical trial were recruited from Bir-
mingham Health Care (BHC), the largest health care
agency for homeless persons in Birmingham, Alabama.
Inclusion criteria were: 1) homeless according to McKin-
ney Act criteria for homelessness [24]; 2) self-reported
cocaine use in the past two weeks with a DSM-III-R diag-
noses of cocaine abuse/dependence at baseline assess-
ment; 3) endorsed significant symptoms of psychological
distress based on a Symptoms Checklist 90-R scale t-scoreSubstance Abuse Treatment, Prevention, and Policy 2006, 1:27 http://www.substanceabusepolicy.com/content/1/1/27
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> 70[25]; 4) intended to stay in Birmingham for 12
months; 5) capable of providing informed consent; 6) no
symptoms of severe medical or psychiatric disorder
requiring immediate hospitalization; and 7) willing to
participate in interventions and assessments.
One hundred sixty-three individuals were screened and
found eligible to participate in the study. However, 16 did
not attend baseline testing, 5 were found ineligible after
reviewing screening assessments, and 1 refused participa-
tion. The remaining 141 individuals were randomly
assigned to 1 of 2 treatment groups, as reviewed below. All
participants provided informed consent, received modest
compensation, and this study had the approval of the
Institutional Review Board of the University of Alabama
at Birmingham.
Design and intervention
Participants were randomized to 1 of 2 interventions:
Enhanced Day Treatment (DT+) and Day Treatment alone
(DT). The trial intervention was a manualized, behavioral
day treatment program occurring in 3 phases. During
Phase I (months 0–2), all participants engaged in a sub-
stance abuse day treatment program from 7:30 am to 2:30
pm, including lunch and transportation to and from the
treatment center. Individuals participated in group and
individual therapy, and underwent urine drug testing.
Day treatment emphasized individualized goal setting
and review of goal attainment in major life domains
(housing, employment, mental health, etc), with weekly
vouchers provided for accomplished goals.
Upon achieving 2 weeks of abstinence, participants in the
DT+ trial arm also received abstinent-contingent, rent-
free, furnished apartments. However, a positive urine
screen on random, twice-weekly testing resulted in imme-
diate eviction of the individual from the rent-free apart-
ment and transportation to a shelter. Individuals could
return to program-provided housing once they re-estab-
lished abstinence (2 consecutive negative urine toxicolo-
gies). Individuals in the DT arm did not have the option
of abstinent-contingent housing but were free to pursue
any other housing options available to them.
During Phase II (months 3–6), both DT+ and DT partici-
pants engaged in aftercare, consisting of weekly 1.5-hour
group therapy sessions that emphasized goal setting and
relapse prevention. Urine was screened at least once
weekly. Individual counseling was available as needed.
For individuals in the DT+ group, abstinent-contingent
housing remained available for a rent of $162 per month.
Rent could be earned through employment or program-
provided abstinent-contingent work therapy. Individuals
in the DT arm did not have the option of abstinent-con-
tingent housing. While their specific lodging experiences
were not recorded, many used local shelters and boarding
and recovery homes.
Primary outcome measures
The primary outcome measure for this analysis was the
presence of current non-psychotic, non-substance abuse/
dependence Axis I psychiatric diagnoses (e.g. depression,
anxiety, etc.) at baseline and 6 months. Baseline diagnos-
tic evaluations were completed 7–12 days following
enrollment into the study. This delay was designed to
reduce diagnostic imprecision resulting from post-cocaine
dysphoric symptoms (including the post-cocaine
"crash"), which are typically most intense during the first
week after cessation [15,26].
Diagnostic assessments, lasting approximately 30 minutes
to 1 hour, were conducted by a psychology post-doctoral
fellow or faculty member, who assigned diagnoses based
on a clinical diagnostic interview, structured with the help
of a computer-administered DSM-III-R Checklist [27].
The checklist is designed to assist doctoral-level clinicians
in establishing diagnoses for 22 Axis I disorders as well as
one Axis II disorder, antisocial personality disorder. It
served as a diagnostic clinical guide in the original Epide-
miologic Catchment Area (ECA) Survey [28]. Its psycho-
metric properties were established based on agreement of
diagnoses with psychiatrist and lay administration of the
Diagnostic Interview Schedule [29]. Specificities of all
diagnoses were 90% or better, while sensitivities ranged
from 47% to 100% [30]. The Checklist, based on DSM-III-
R, did not explicitly provide a method to delineate inde-
pendent from secondary comorbid psychiatric diagnoses
(unlike instruments based on the DSM-IV [31,32]. How-
ever, consistent with the DSM-III-R, diagnostic evaluators
were expected to delineate primary disorders based on a
global, albeit unguided, clinical judgment. Clinical judg-
ment was also applied to participants with symptoms out-
side of the scope of the instrument (e.g. trichotillomania).
Each participant provided data at baseline and at the end
of Phase II (i.e. at the 6-month follow-up). For purposes
of profiling the baseline distribution of diagnoses, indi-
viduals were categorized into 1 of 4 diagnostic groups. The
first group consisted of individuals with only anxiety-
related disorders (ARDs) (e.g. post-traumatic stress disor-
der, generalized anxiety disorder, and others). The second
group consisted of individuals with only mood-related
disorders (MRDs) (e.g. depression, dysthymia, and oth-
ers). The third group consisted of individuals with both
MRDs and ARDs (Combo). The remaining individuals
had neither ARD nor MRD comorbid diagnoses (None).
See Table 1 for details.Substance Abuse Treatment, Prevention, and Policy 2006, 1:27 http://www.substanceabusepolicy.com/content/1/1/27
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Covariates
In modeling changes in the prevalence of the 2 psychiatric
disorder categories (ARDs and MRDs) over 6-months,
analyses took into account several measures that could
plausibly be related to these outcomes and might be con-
strued as confounders or explanatory variables. Age, edu-
cation, gender and race were included as demographic
covariates. Abstinence was defined as the longest number
of consecutive weeks abstinent, as measured by drug-neg-
ative urine toxicologies, during the time frame encom-
passed by the present analysis (i.e. 6 months). Trial arm
assignment (DT and DT+) and treatment attendance were
also included as covariates to ascertain the impact of treat-
ment intensity on outcome. Attendance was categorized,
based on review of the biphasic distribution of participa-
tion in outpatient day treatment in Phase I (months 1–2)
and Phase II (3–6), thusly: "low" (low attendance in both
Phase I and Phase II), "medium" (high attendance in
Phase I or Phase II, but not both Phases) and "high" (high
attendance in both Phase I and Phase II).
Data analysis
To assess the relationship between disorder type (ARD
and MRD) and time (0 months, 6 months), this analysis
included data for individuals available at baseline and 6
months. To assess the potential for selection bias, baseline
characteristics for included participants to those partici-
pants unavailable at six months were compared with
Mann-Whitney U tests and chi-squared tests as indicated.
To evaluate whether mood and anxiety disorder outcomes
differed for participants who contributed observations at
baseline and follow-up, the outcome of psychiatric disor-
der (presence/absence) was modeled in relation to disor-
der type (ARD and MRD) and time (0 months and 6
months) using an extension of the generalized linear
model, a generalized estimating equation [33]. To allow
model specification that could address the questions of
interest, 4 binary outcomes were generated for each partic-
ipant based on disorder type at each time period. For
many readers, the inclusion of the type of disorder and the
time of the observation interval as predictors for a generic
outcome of "psychiatric disorder present/absent" will not
seem intuitive, but this approach permits statistically test-
ing whether psychiatric disorder presence was dependent
on observation interval (i.e., baseline versus 6 months
later) and whether it differed for anxiety-related as
opposed to mood-related disorders. This approach is
analogous to an extension of the McNemar test often used
for paired binary outcomes (the ARD and MRD diag-
noses) in a longitudinal setting. This GEE approach incor-
porates the between-diagnostic-category and temporal
correlation inherent to this study design.
A hierarchical modeling approach [34] was employed to
analyze the data. A base model (including only the obser-
vation interval and type of disorder) was specified, fol-
lowed by 3 additional exploratory models, which varied
in regard to the inclusion of 3 groups of plausible covari-
ates chosen a priori (i.e. demographic, abstinence-related,
and treatment intensity-related covariates). All 4 models
included the disorder type and observation interval as pre-
dictors, co-represented as 4 predictor terms (ARD at base-
line, ARD at 6 months, MRD at baseline, MRD at 6
months), along with a separate term for observation inter-
val (baseline versus 6 months) representing the effect of
interval time, independent of disorder type. Model 1
included only these 4 disorder/interval terms and the term
for interval. Model 2 included these 5 terms, and the
demographic covariates of gender, race, education and
age. Model 3 included the same 5 terms as Model 1, and
consecutive weeks of abstinence. Model 4 included the
same 5 terms, two treatment intensity covariates [trial arm
assignment (DT or DT+) and day treatment attendance].
Potential evidence of treatment benefit was sought
through post hoc testing for the 3-way interactions of dis-
order type by time by treatment arm, and of disorder type
by time by attendance. Recognizing that such analyses
should be considered exploratory given the small num-
bers of subjects, p-values are offered as indicators of the
likelihood of potential associations, rather than formal
hypothesis testing.
SAS Version 8.0 (SAS Institute, 2001, Cary, NC) was the
statistical software package used for all statistical analyses.
Table 1: Most Frequent Baseline Diagnoses in the Analytic 
Cohort (n = 95)1
Disorder Frequency Percentage2
Major Depressive Disorder 35 36.8%
Post-traumatic Stress Disorder 21 22.1%
Dysthymia 12 12.6%
Generalized Anxiety Disorder 11 11.6%
Simple Phobia 10 10.5%
Social Phobia 9 9.5%
Adjustment Disorder 7 7.4%
Bipolar Disorder 7 7.4%
Obsessive-Compulsive Disorder 4 4.2%
None 26 27.4%
Notes for Table 1
1. The analytic cohort is restricted to those participants available at 
baseline and follow-up at 6 months (N = 95 of 127 original 
participants).
2. Percentages add up to greater than 100% because participants were 
eligible for multiple diagnoses. Each of the following diagnoses were 
applied only once: Trichotillomania, Agoraphobia without Panic 
Disorder, Alcohol-induced Psychotic Disorder, Anxiety Disorder Not 
Otherwise Specified (NOS), Delusional Disorder NOS, Dementia 
Alzheimer's Type, Dementia NOS, Dissociative Disorder NOS, Eating 
Disorder NOS, Insomnia NOS, Pain Disorder, Paraphilia NOS, and 
Tic Disorder NOS.Substance Abuse Treatment, Prevention, and Policy 2006, 1:27 http://www.substanceabusepolicy.com/content/1/1/27
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Results
Of the initial 141 individuals enrolled in the study, 127
completed DSM-III-R assessments at baseline (DT+ = 69,
DT = 58), and 95 of these 127 (74.8%) individuals pro-
vided complete data at the 6-month follow-up. Table 1
lists the prevalence of the most common disorders among
trial participants at baseline. A comparison of analyzed
participants (persons providing complete data at baseline
and at the 6-month follow-up, n = 95) to individuals pro-
viding only baseline data (n = 32), revealed no significant
differences between groups on demographic variables,
diagnostic categorization, and baseline abstinence (Table
2). The final sample consisted predominantly of young/
middle-aged (mean age = 37.7 ± 7.1 years), African-Amer-
ican (86.3%) males (74.7%) with some college education
(mean education = 13.0 ± 2.0 years). All participants met
criteria for 1 or more current substance abuse/dependence
disorders, with cocaine (96.9%) and alcohol disorders
(57.8%) occurring most frequently, as has been detailed
in another report [35].
At baseline, 69 of 95 individuals (73%) also met criteria
for at least 1 current additional non-substance abuse/
dependence, non-psychotic, Axis I psychiatric disorder. As
shown in Table 3, 26% of participants had MRD with no
ARD, 11% had ARD but no MRD, 33% had both disorder
types, while 3% had a disorder not falling into either cat-
egory. Despite efforts to exclude individuals at the time of
screening with psychotic disorders, two individuals
enrolled in the study later met criteria for alcohol-induced
psychotic disorder and delusional disorder NOS, respec-
tively. The most common MRDs were Major Depressive
Disorder (n = 35), Dysthymia (n = 12), Adjustment Disor-
der (n = 7) and Bipolar Disorder (n = 7). The most com-
mon ARDs were Post-traumatic Stress Disorder (n = 21),
Generalized Anxiety Disorder (n = 11), and Simple Pho-
bia (n = 10).
At 6 months, 39 participants (41%) had at least 1 non-
substance abuse/dependence, non-psychotic, Axis I psy-
chiatric disorder, with similar proportions having MRDs
and ARDs (16% with MRD but no ARD; 13% with ARD
but no MRD; 11% with both MRD and ARD; 2% with a
disorder in neither category). Figure 1 shows the propor-
tion of participants diagnosed with MRDs and ARDs  at
baseline and at 6-month follow-up. Table 3 displays the
frequency for  each disorder type separately and in combi-
nation.
The GEE analyses (Model 1) revealed a significant inde-
pendent effect of observation interval, consistent with
26% lower prevalence of non-substance abuse psychiatric
disorders at 6 month follow-up compared to baseline,
independent of the type of disorder (χ2 [df 1] = 30.49, p <
0.001). The model-derived baseline-to-6-month change
in the proportion of participants with MRDs (-33%),
when tested in Model 1, was not statistically significantly
greater than the change for ARDs (-20%) (χ2 [df 1] = 2.48,
p = 0.12). The reduction in prevalence of MRDs and
ARDs, from 0 to 6 months, is depicted in Figure 1. The
addition of demographic variables to the model (Model
2) revealed that female gender was associated with a 19%
greater likelihood of having any disorder (χ2 [df 1] = 2.32,
p = 0.007). No other demographic variables were associ-
ated with psychiatric disorder presence. The abstinence
indicator variables (Model 3) were not associated with
psychiatric disorder presence (all p > 0.50, data not
shown). Models including treatment intensity covariates
(trial arm and attendance) did not suggest clear associa-
tions with either variable (Model 4). There was no signif-
Table 2: Comparison of Individuals Providing Only Baseline Data and Individuals Providing Complete Data at Baseline and at Six 
Months' Follow-Up
Characteristic1 Baseline Only (n = 32) Available at Baseline and 6 months (n = 95) Statistical Test2 p
Age 38.97 (7.96) 37.65 (7.10) U = 1391.5 0.59
Race (% AA) 71.9 86.3 χ2 = 3.49 0.06
Gender (% male) 68.8 74.7 χ2 = 0.44 0.51
Education 12.93 (3.45) 13.03 (2.02) U = 1465 0.76
Diagnostic Category at Baseline (%) χ2 (df 3) = 0.08 0.99
ARD Only (%) 9.4 10.5
MRD Only (%) 28.1 26.3
Combo (%) 31.3 32.6
None (%) 31.3 30.5
Abstinent (%)3 100.0 98.9 χ2 = 0.34 0.56
Anti-social Personality Disorder (%) 28.1 31.6 χ2 = 0.13 0.71
Table Notes
1. Abbreviations: ARD = anxiety-related disorder; MRD = mood-related disorder; Combo = presence of both ARD and MRD; AA = African 
American.
2. Continuous variables are compared with the Mann-Whitney U-Test, and categorical variables are compared with the χ2 test (df = 1 for all 
comparisons except where noted).
3. Abstinent (%) refers to abstinence at baseline, by urine test in the first few days after entering treatmentSubstance Abuse Treatment, Prevention, and Policy 2006, 1:27 http://www.substanceabusepolicy.com/content/1/1/27
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icant 3-way interaction of disorder type by time by
treatment assignment (χ2 [df 3] = 0.25, p = 0.97) or disor-
der type by time and by attendance (χ2 [df 6] = 3.87 p =
0.69).
Discussion
Psychiatric comorbidity is common among homeless
individuals presenting for addiction treatment. Data
regarding the prognosis for comorbid psychiatric disor-
ders among cocaine abusers undergoing behaviorally-
based addiction treatment are infrequent [17,18], espe-
cially among homeless samples. In this study at baseline,
73% of a homeless cocaine-abusing sample qualified for
1 or more comorbid disorders. Common diagnoses
included depression and post-traumatic stress disorder.
This proportion fell to 41% at 6 months. Multivariable
analyses did not demonstrate associations of trial arm or
treatment intensity (including attendance) with improve-
ment for either disorder type, but these statistical models
were quite substantially underpowered, relying upon 3-
way interaction terms with small subject numbers.
More than one interpretation for these findings is entirely
possible. For instance, these findings may reflect a "spillo-
ver psychiatric benefit" for a behavioral addiction treat-
ment program that offered elements of behavioral
activation, social and tangible rewards, and milieu ther-
apy. Conversely, evidence of improvement over time may
simply indicate that (a) emotional dysphoria character-
izes many persons early in the course of addiction treat-
ment, and (b) dysphoric symptoms early in treatment can
suggest psychiatric diagnoses, and (c) such symptoms
tend to abate. Only a non-treatment control arm, some-
thing not present in this study and not frequently availa-
ble in research involving homeless populations, could
definitively disentangle these and other possible explana-
tions.
Our findings may be compared to studies that have shown
improvements in psychiatric symptoms among dually
diagnosed inpatients [12,36] and community-dwelling
outpatients [37] who received integrated treatment pro-
grams with services for comorbid addiction and nonad-
diction psychiatric problems. However those studies
relied on brief measures of psychiatric symptoms and
functioning [38], rather than the more specific diagnostic
assessments used in this study, and they involved pro-
grams that formally integrated addiction and psychiatric
services, a potentially desirable approach that is not con-
sistently funded in many communities. Since this trial was
Percentage of Participants with Mood-Related Disorders  (MRDs) and Anxiety-Related Disorders (ARDs) at Baseline  and at 6-month Follow-up Figure 1
Percentage of Participants with Mood-Related Disor-
ders (MRDs) and Anxiety-Related Disorders (ARDs) 
at Baseline and at 6-month Follow-up. Ninety-five 
homeless, cocaine-dependent treatment trial participants 
were diagnostically assessed at baseline and at 6 months' fol-
low-up for the presence of Mood-Related Disorders (MRDs) 
or Anxiety-Related Disorders (ARDs), using a clinical inter-
view conducted by a trained psychologist. MRDs included 
disorders such as depression and bipolar disorder. ARDs 
included disorders such as post-traumatic stress disorder 
and generalized anxiety disorder (for details, see Methods). 
The figure depicts the prevalence of each disorder type 
(MRDs and ARDs) among this sample at baseline and 6 
months. The 32% absolute decline in prevalence of non-
addiction psychiatric disorders from baseline to 6 months 
corresponds to -26% change in a statistical model adjusting 
for disorder type, and accounting for multiple observations 
per person. (χ2 [df 1] = 30.49, p < 0.001). A test of whether 
the decline in MRD prevalence from 0 to 6 months differed 
from the decline for ARDs was nonsignificant, (χ2 [df 1] = 
2.48, p = 0.12).
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Table 3: Frequency of Disorders, By Category of Mood-versus 
Anxiety-Related Disorder at Baseline and 6 Months
Category Baseline [n (%)] Follow-up [n (%)]
Mood-Related Disorder (MRD) 25 (26%) 15 (16%)
MRD Only 24 14
MRD + Other1 11
Anxiety-Related Disorder (ARD) 10 (11%) 12 (13%)
ARD Only 10 12
ARD + Other1 00
Combination (MRD and ARD) 31 (33%) 10 (11%)
MRD + ARD 26 9
MRD + ARD + Other1 51
Neither MRD nor ARD 29 (31%) 58 (61%)
Other Only1 32
Total with Any Comorbid Disorder 69 (73%) 39 (41%)
Total with No Comorbid Disorder 26 (27%) 56 (59%)
Total Participants 95 (100%) 95 (100%)
Notes
1. "Other" refers to disorders other than Mood- or Anxiety-Related 
Disorders and includes Trichotillomania, Alcohol-induced Psychotic 
Disorder, Delusional Disorder NOS, Dementia Alzheimer's Type, 
Dementia NOS, Dissociative Disorder NOS, Eating Disorder NOS, 
Insomnia NOS, Pain Disorder, Paraphilia NOS, and Tic Disorder NOS.Substance Abuse Treatment, Prevention, and Policy 2006, 1:27 http://www.substanceabusepolicy.com/content/1/1/27
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conducted in a state where neither Medicaid nor free psy-
chiatric care are freely accessible to single adults with
nonpsychotic mental illness, these findings may reflect
what results can be expected from behavioral addiction
treatment, absent formal psychiatric treatment services.
An interpretive challenge for this study is the degree to
which the findings reflect the remission of substance-
induced psychiatric disorders or withdrawal symptoms,
rather than remission of independent psychiatric disor-
ders. The diagnostic method used here makes the first
interpretation somewhat less plausible. Evaluations were
formally structured, conducted by doctoral-level individ-
uals, and occurred 7–12 days after last use (e.g. after the
period when the most prominent mood dsyphoria is typ-
ically reported by cocaine users in treatment [26]). None-
theless there remains debate regarding the applicability of
psychiatric diagnostic terms to individuals early in addic-
tion recovery [39], and future research in this area should
include instruments that formally address the distinction
of independent and secondary psychiatric disorders, such
as the Psychiatric Research Interview for Substance and
Mental Disorders (PRISM) [39,31].
Limitations to the present analysis, notably sample size
and power, have been noted. In the homeless population,
however, there is a lack of other studies that have accrued
and subjected to formal psychological diagnosis a simi-
larly-sized sample of dually diagnosed cocaine abusers up
to 6 months after behavioral treatment.
Important strengths to this study include its being among
the few to focus on psychiatric outcomes in dually diag-
nosed homeless individuals with non-psychotic disor-
ders. Homeless individuals in particular represent a
distinctly challenging group for the conduct of prospec-
tive research. For a study of homeless persons with crack-
cocaine addictions and high rates of comorbidity, a 6-
month follow-up rate of 74.8% compares favorably with
similar studies [40,41].
Implications
These findings should be relevant to policymakers, given
ongoing governmental interest in both chronic homeless-
ness and addiction treatment, coupled with limitations on
access to specialty psychiatric care. A recent managed care
consensus panel's recommendations for treating dually
diagnosed individuals suggests that addiction treatment
programs must be ready to respond to comorbid psychiat-
ric disorders [42,43]. Problematically, few dual diagnosis
treatment options are empirically validated among non-
psychotic, homeless populations. Moreover, only 35% of
addiction treatment programs offer programs and services
for persons with comorbid mental illness [11]. The reduc-
tion in psychiatric disorder prevalence observed in this
sample, if confirmed in future trials, suggests a potential
secondary benefit to behavioral addiction treatment for
some dually diagnosed homeless. However, over 40% of
this cohort continued to qualify for nonaddiction psychi-
atric diagnoses at 6 months. Accordingly, even if evidence-
based, comprehensive behavioral addiction treatment
were to become the norm in publicly funded programs,
many homeless individuals are still likely to require psy-
chiatric specialty care in conjunction with addiction treat-
ment.
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